Medicus Pharma Advances Skinject Toward FDA Pivotal Trial for Skin Cancer

Medicus Pharma (NASDAQ: MDCX) has released expanded Phase 2 analysis for its Skinject microneedle therapy, showing promising results in the treatment of basal cell carcinoma, the most common form of skin cancer. The company says the study demonstrated a strong dose response using its 200-microgram microneedle patch, positioning the therapy for an upcoming end-of-Phase-2 meeting with the FDA.

Skinject uses a patented dissolvable microneedle array to deliver localized microdoses of chemotherapy directly into skin cancer lesions, potentially reducing the need for invasive surgery. Medicus believes the therapy could offer a more cost-effective and cosmetically favorable alternative for many patients while addressing significant treatment backlogs in dermatology care.

#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#Oncology
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Microneedles
#Dermatology
#FDA
#JaneKing
#NewsOut